Patents by Inventor Meik Sladek

Meik Sladek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGH DOSE AND LOW VOLUME BOTULINUM TOXIN TREATMENT OF FACIAL WRINKLES
    Publication number: 20230329996
    Abstract: The present invention relates the use of botulinum toxin for the treatment of facial wrinkles, wherein botulinum toxin is administered at high doses (e.g., 50 U to 200 U) using small injection volumes (e.g., 0.05 ml to 0.35 ml). Furthermore, the present invention relates to a method for the treatment of facial wrinkles (e.g., glabellar frown lines) by injecting small volumes of a highly concentrated botulinum toxin solution into a target facial area of a subject.
    Type: Application
    Filed: June 4, 2021
    Publication date: October 19, 2023
    Inventors: Susanna ROLL, Meik SLADEK, Thorin GEISTER, Irena PULTE, Petra WEISSENBERGER, Gudrun KLEIN
  • Glycine B antagonist
    Patent number: 8288549
    Abstract: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: October 16, 2012
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Markus Henrich, Angela Bauer, Jens Nagel, Meik Sladek, Christopher Graham Raphael Parsons, Wojciech Danysz, Valerjans Kauss, Jevgenijs Rozhkovs, Igors Starchenkovs, Dina Trifanova
  • GLYCINE B ANTAGONIST
    Publication number: 20110190342
    Abstract: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.
    Type: Application
    Filed: September 30, 2009
    Publication date: August 4, 2011
    Inventors: Markus Henrich, Angela Bauer, Jens Nagel, Meik Sladek, Christopher Graham Raphael Parsons, Wojciech Danysz, Valerjans Kauss, Jevgenijs Rozhkovs, Igos Starchenkovs, Dina Trifanova